Get started

Financials · CCCC

C4 Therapeutics Inc. (CCCC) financials

For the twelve months ended Sep 30, 2026, C4 Therapeutics Inc. reported $32.28M of revenue and -$91.09M of net income.

Revenue, TTM
$32.28M
Revenue growth, YoY
+7.2%
Net income, TTM
-$91.09M
Net margin
-282.2%
Free cash flow, TTM
-$79.74M
EPS, diluted, TTM
-$0.63
Cash
$32.42M
P/S
12.82
Market cap
$413.7M
Annual revenue$35.95M
FY2021FY2025
Annual net income-$104.99M
FY2019FY2025
Annual free cash flow-$99.30M
FY2019FY2025

CCCC revenue and earnings growth

CCCC revenueQ3 2026$8.47M

Quarter YoY
-24.6%
QoQ
+27.5%
FY YoY
+1.0%

CCCC revenue was $8.47M in fiscal Q3 2026 (ended Sep 30, 2026), down 24.6% from a year earlier and up 27.5% from the prior quarter. For the full fiscal 2025 it was $35.95M, up 1.0% from fiscal 2024. It rose in 2 of the last 4 fiscal years.

CCCC net incomeQ3 2026-$21.84M

CCCC net income was -$21.84M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$32.17M a year earlier. For the full fiscal 2025 it was -$104.99M, compared with -$105.32M in fiscal 2024.

CCCC EPSQ3 2026-$0.16

CCCC diluted EPS was -$0.16 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.27, compared with -$1.52 in fiscal 2024.

CCCC free cash flowQ3 2026-$25.97M

CCCC free cash flow was -$25.97M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$31.62M a year earlier. For the full fiscal 2025 it was -$99.30M, compared with -$65.34M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$35.95M$35.58M$20.76M$31.10M$45.78M--
Research and development$104.24M$110.64M$117.71M$117.84M$94.67M$78.44M$48.06M
Selling, general and admin$36.20M$42.12M$42.08M$42.79M$33.25M$15.20M$8.77M
Operating income-$115.22M-$119.61M-$139.03M-$129.53M-$82.13M-$60.45M-$35.45M
Pre-tax income-$104.87M-$105.19M-$131.21M-$128.18M-$83.89M-$66.96M-$33.30M
Income tax$121.0K$131.0K$1.28M$0$0-$626.0K$804.0K
Net income-$104.99M-$105.32M-$132.49M-$128.18M-$83.89M-$66.33M-$34.10M
EPS, basic-$1.27-$1.52-$2.67-$2.62-$1.82-$5.83-$31.03
EPS, diluted-$1.27-$1.52-$2.67-$2.62-$1.82-$5.83-$31.03
Diluted shares82.9M69.4M49.6M48.9M46.0M11.4M1.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$74.60M$58.94M$130.03M$33.03M$79.40M$184.30M$90.55M
Short-term investments----$233.16M$189.96M-
Receivables$2.40M$3.10M$11.80M$1.47M$5.72M$4.48M$4.62M
Current assets$258.11M$257.77M$271.19M$287.56M$325.69M$381.01M$96.77M
Total assets$359.07M$349.60M$376.45M$430.84M$506.76M$400.14M$118.26M
Current liabilities$33.03M$45.18M$42.77M$44.55M$51.25M$43.85M$33.64M
Short-term debt--$0$2.29M$0--
Long-term debt--$0$9.20M$10.77M$10.05M-
Total debt--$0$11.48M$10.77M$10.05M-
Total liabilities$102.49M$133.62M$130.34M$141.61M$117.16M$119.35M$119.23M
Shareholders' equity$256.59M$215.99M$246.11M$289.23M$389.61M$280.79M-$111.96M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$98.69M-$65.16M-$106.84M-$105.94M-$86.97M-$67.25M$55.61M
Capital expenditures$607.0K$180.0K$1.71M$5.50M$1.28M$650.0K$1.35M
Free cash flow-$99.30M-$65.34M-$108.55M-$111.44M-$88.24M-$67.90M$54.27M
Investing cash flow-$8.60M-$51.27M$158.35M$58.42M-$189.34M-$190.50M-$1.62M
Financing cash flow$126.40M$45.34M$45.49M$1.15M$171.40M$348.93M$244.0K
Share repurchases$193.0K$194.0K$110.0K$0-$194.0K$30.0K
Stock-based compensation$19.10M$29.66M$27.23M$30.02M$21.51M$3.43M$1.64M
Depreciation and amortization$1.96M$1.82M$1.88M$1.68M$1.49M$1.62M$1.59M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY1.0%71.4%-33.3%-32.1%---
Operating margin-320.5%-336.1%-669.8%-416.6%-179.4%--
Net margin-292.1%-296.0%-638.3%-412.2%-183.2%--
Free cash flow margin-276.2%-183.6%-523.0%-358.4%-192.7%--
Return on equity-40.9%-48.8%-53.8%-44.3%-21.5%-23.6%-
Return on assets-29.2%-30.1%-35.2%-29.8%-16.6%-16.6%-28.8%
Current ratio7.815.716.346.466.368.692.88
Debt to equity--0.000.040.030.04-

Source: XBRL data C4 Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CCCC peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CCCC$32.28M+7.2%-$91.09M-282.2%$413.7M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

CCCC FAQ

8 questions
  • What is CCCC revenue?
    C4 Therapeutics Inc. (CCCC) reported $32.28M of revenue for the twelve months ended Sep 30, 2026. That is up 7.2% from the year before. Revenue for fiscal 2025 was $35.95M.
  • Is CCCC profitable?
    No. C4 Therapeutics Inc. reported a net loss of $91.09M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CCCC have?
    C4 Therapeutics Inc. reported $32.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CCCC revenue growing?
    C4 Therapeutics Inc.'s revenue changed +1.0% in fiscal 2025, to $35.95M.
  • What is CCCC free cash flow?
    C4 Therapeutics Inc. generated -$79.74M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$79.63M less capital expenditures.
  • What is CCCC earnings per share?
    Diluted earnings per share were -$0.63 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CCCC last report financial results?
    The latest statements here come from C4 Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this CCCC financial data come from?
    Quantisnow builds these statements from the structured XBRL data C4 Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.